Transfusion- and community-acquired cytomegalovirus infection in children with malignant disease

A prospective study

J. K. Preiksaitis, S. Desai, W. Vaudry, S. Roberts, J. Akabutu, P. Grundy, B. Wilson, Lynn Boshkov, J. Hannon, M. Joffres

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

BACKGROUND: The use of cytomegalovirus (CMV)- 'safe' blood has been recommended for CMV seronegative patients with newly diagnosed malignant disease for whom bone marrow transplantation is a future option. STUDY DESIGN AND METHODS: To evaluate this policy, 76 CMV-seronegative children with lymphoreticular malignancies or solid tumors were randomly assignee to receive either blood components that were not screened for CMV antibody or CMV-seronegative red cell (RBC) and platelet units. Subjects were followed for evidence of CMV infection by the use of enzyme-linked immunosorbent assays and virus isolation. Follow-up continued long after the blood transfusions to determine the risk of community-acquired CMV infection. RESULTS: No cases of transfusion-acquired CMV infection were documented. The prevalence of CMV IgG and IgM antibody in blood donors was 40.5 and 0.9 percent, respectively. Patients assigned to receive standard blood components and CMV-negative components were given a median (range) of 7 (1-30) and 9 (1- 38) RBC units and 11 (0-123) and 14 (0-71) platelet units, respectively. The risk of transfusion-acquired CMV infection is estimated to be less than 1 in 698 donor exposures. Two patients developed asymptomatic community-acquired CMV infection, for an incidence of 1.7 percent per patient-year of follow- up. CONCLUSION: The risk of transfusion-acquired CMV infection in this population is low, largely because of the patients' low level of exposure to seropositive blood and the use of relatively white cell-reduced components for purposes other than CMV prevention. Such children at this center therefore continue to receive standard blood components. Strategies to prevent CMV seroconversion in these children should include parental education to minimize the risk of community-acquired infection.

Original languageEnglish (US)
Pages (from-to)941-946
Number of pages6
JournalTransfusion
Volume37
Issue number9
StatePublished - Sep 1997

Fingerprint

Community-Acquired Infections
Cytomegalovirus Infections
Cytomegalovirus
Prospective Studies
Blood Platelets
Antibodies
Cellular Structures
Blood Donors
Bone Marrow Transplantation
Blood Transfusion
Immunoglobulin M
Neoplasms
Immunoglobulin G
Enzyme-Linked Immunosorbent Assay
Tissue Donors
Viruses
Education

ASJC Scopus subject areas

  • Hematology
  • Immunology

Cite this

Preiksaitis, J. K., Desai, S., Vaudry, W., Roberts, S., Akabutu, J., Grundy, P., ... Joffres, M. (1997). Transfusion- and community-acquired cytomegalovirus infection in children with malignant disease: A prospective study. Transfusion, 37(9), 941-946.

Transfusion- and community-acquired cytomegalovirus infection in children with malignant disease : A prospective study. / Preiksaitis, J. K.; Desai, S.; Vaudry, W.; Roberts, S.; Akabutu, J.; Grundy, P.; Wilson, B.; Boshkov, Lynn; Hannon, J.; Joffres, M.

In: Transfusion, Vol. 37, No. 9, 09.1997, p. 941-946.

Research output: Contribution to journalArticle

Preiksaitis, JK, Desai, S, Vaudry, W, Roberts, S, Akabutu, J, Grundy, P, Wilson, B, Boshkov, L, Hannon, J & Joffres, M 1997, 'Transfusion- and community-acquired cytomegalovirus infection in children with malignant disease: A prospective study', Transfusion, vol. 37, no. 9, pp. 941-946.
Preiksaitis JK, Desai S, Vaudry W, Roberts S, Akabutu J, Grundy P et al. Transfusion- and community-acquired cytomegalovirus infection in children with malignant disease: A prospective study. Transfusion. 1997 Sep;37(9):941-946.
Preiksaitis, J. K. ; Desai, S. ; Vaudry, W. ; Roberts, S. ; Akabutu, J. ; Grundy, P. ; Wilson, B. ; Boshkov, Lynn ; Hannon, J. ; Joffres, M. / Transfusion- and community-acquired cytomegalovirus infection in children with malignant disease : A prospective study. In: Transfusion. 1997 ; Vol. 37, No. 9. pp. 941-946.
@article{92e4d160d65d442ab060a803dd7c86f1,
title = "Transfusion- and community-acquired cytomegalovirus infection in children with malignant disease: A prospective study",
abstract = "BACKGROUND: The use of cytomegalovirus (CMV)- 'safe' blood has been recommended for CMV seronegative patients with newly diagnosed malignant disease for whom bone marrow transplantation is a future option. STUDY DESIGN AND METHODS: To evaluate this policy, 76 CMV-seronegative children with lymphoreticular malignancies or solid tumors were randomly assignee to receive either blood components that were not screened for CMV antibody or CMV-seronegative red cell (RBC) and platelet units. Subjects were followed for evidence of CMV infection by the use of enzyme-linked immunosorbent assays and virus isolation. Follow-up continued long after the blood transfusions to determine the risk of community-acquired CMV infection. RESULTS: No cases of transfusion-acquired CMV infection were documented. The prevalence of CMV IgG and IgM antibody in blood donors was 40.5 and 0.9 percent, respectively. Patients assigned to receive standard blood components and CMV-negative components were given a median (range) of 7 (1-30) and 9 (1- 38) RBC units and 11 (0-123) and 14 (0-71) platelet units, respectively. The risk of transfusion-acquired CMV infection is estimated to be less than 1 in 698 donor exposures. Two patients developed asymptomatic community-acquired CMV infection, for an incidence of 1.7 percent per patient-year of follow- up. CONCLUSION: The risk of transfusion-acquired CMV infection in this population is low, largely because of the patients' low level of exposure to seropositive blood and the use of relatively white cell-reduced components for purposes other than CMV prevention. Such children at this center therefore continue to receive standard blood components. Strategies to prevent CMV seroconversion in these children should include parental education to minimize the risk of community-acquired infection.",
author = "Preiksaitis, {J. K.} and S. Desai and W. Vaudry and S. Roberts and J. Akabutu and P. Grundy and B. Wilson and Lynn Boshkov and J. Hannon and M. Joffres",
year = "1997",
month = "9",
language = "English (US)",
volume = "37",
pages = "941--946",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Transfusion- and community-acquired cytomegalovirus infection in children with malignant disease

T2 - A prospective study

AU - Preiksaitis, J. K.

AU - Desai, S.

AU - Vaudry, W.

AU - Roberts, S.

AU - Akabutu, J.

AU - Grundy, P.

AU - Wilson, B.

AU - Boshkov, Lynn

AU - Hannon, J.

AU - Joffres, M.

PY - 1997/9

Y1 - 1997/9

N2 - BACKGROUND: The use of cytomegalovirus (CMV)- 'safe' blood has been recommended for CMV seronegative patients with newly diagnosed malignant disease for whom bone marrow transplantation is a future option. STUDY DESIGN AND METHODS: To evaluate this policy, 76 CMV-seronegative children with lymphoreticular malignancies or solid tumors were randomly assignee to receive either blood components that were not screened for CMV antibody or CMV-seronegative red cell (RBC) and platelet units. Subjects were followed for evidence of CMV infection by the use of enzyme-linked immunosorbent assays and virus isolation. Follow-up continued long after the blood transfusions to determine the risk of community-acquired CMV infection. RESULTS: No cases of transfusion-acquired CMV infection were documented. The prevalence of CMV IgG and IgM antibody in blood donors was 40.5 and 0.9 percent, respectively. Patients assigned to receive standard blood components and CMV-negative components were given a median (range) of 7 (1-30) and 9 (1- 38) RBC units and 11 (0-123) and 14 (0-71) platelet units, respectively. The risk of transfusion-acquired CMV infection is estimated to be less than 1 in 698 donor exposures. Two patients developed asymptomatic community-acquired CMV infection, for an incidence of 1.7 percent per patient-year of follow- up. CONCLUSION: The risk of transfusion-acquired CMV infection in this population is low, largely because of the patients' low level of exposure to seropositive blood and the use of relatively white cell-reduced components for purposes other than CMV prevention. Such children at this center therefore continue to receive standard blood components. Strategies to prevent CMV seroconversion in these children should include parental education to minimize the risk of community-acquired infection.

AB - BACKGROUND: The use of cytomegalovirus (CMV)- 'safe' blood has been recommended for CMV seronegative patients with newly diagnosed malignant disease for whom bone marrow transplantation is a future option. STUDY DESIGN AND METHODS: To evaluate this policy, 76 CMV-seronegative children with lymphoreticular malignancies or solid tumors were randomly assignee to receive either blood components that were not screened for CMV antibody or CMV-seronegative red cell (RBC) and platelet units. Subjects were followed for evidence of CMV infection by the use of enzyme-linked immunosorbent assays and virus isolation. Follow-up continued long after the blood transfusions to determine the risk of community-acquired CMV infection. RESULTS: No cases of transfusion-acquired CMV infection were documented. The prevalence of CMV IgG and IgM antibody in blood donors was 40.5 and 0.9 percent, respectively. Patients assigned to receive standard blood components and CMV-negative components were given a median (range) of 7 (1-30) and 9 (1- 38) RBC units and 11 (0-123) and 14 (0-71) platelet units, respectively. The risk of transfusion-acquired CMV infection is estimated to be less than 1 in 698 donor exposures. Two patients developed asymptomatic community-acquired CMV infection, for an incidence of 1.7 percent per patient-year of follow- up. CONCLUSION: The risk of transfusion-acquired CMV infection in this population is low, largely because of the patients' low level of exposure to seropositive blood and the use of relatively white cell-reduced components for purposes other than CMV prevention. Such children at this center therefore continue to receive standard blood components. Strategies to prevent CMV seroconversion in these children should include parental education to minimize the risk of community-acquired infection.

UR - http://www.scopus.com/inward/record.url?scp=9844229887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9844229887&partnerID=8YFLogxK

M3 - Article

VL - 37

SP - 941

EP - 946

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 9

ER -